Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher
Crossmark

Anti-Obesity Drug Orlistat (Xenical) Is a Novel Antitumor Medication

Leila Azadbakht 1 , Zahra Jamali-Gojani 1 and Motahar Heidari-Beni 1 , *
Authors Information
1 Food Security Research Center, Department of Community Nutrition, School of Nutrition & Food Sciences, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Shiraz E-Medical Journal: January 01, 2015, 16 (1); e26242
  • Published Online: January 17, 2015
  • Article Type: Research Article
  • Received: December 20, 2014
  • Accepted: December 22, 2014
  • DOI: 10.17795/semj26242

To Cite: Azadbakht L, Jamali-Gojani Z, Heidari-Beni M. Anti-Obesity Drug Orlistat (Xenical) Is a Novel Antitumor Medication, Shiraz E-Med J. 2015 ; 16(1):e26242. doi: 10.17795/semj26242.

Abstract
Copyright © 2015, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
References
  • 1. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer. 2006; 118(10): 2628-31[DOI][PubMed]
  • 2. Azadbakht L, Esmaillzadeh A. Dietary and non-dietary determinants of central adiposity among Tehrani women. Public Health Nutr. 2008; 11(5): 528-34[DOI][PubMed]
  • 3. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005; 28(12): 2823-31[PubMed]
  • 4. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000; 8(1): 49-61[DOI][PubMed]
  • 5. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004; 64(6): 2070-5[PubMed]
  • 6. Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011; 65(4): 286-92[DOI][PubMed]
  • 7. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res. 2006; 66(11): 5934-40[DOI][PubMed]
  • 8. Menendez JA, Vellon L, Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood). 2005; 230(3): 151-4[PubMed]
  • 9. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005; 16(8): 1253-67[DOI][PubMed]
  • 10. Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer. 2012; 107(6): 977-87[DOI][PubMed]
  • 11. Garcia SB, Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, et al. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006; 240(2): 221-4[DOI][PubMed]
  • 12. Gelebart P, Zak Z, Anand M, Belch A, Lai R. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS One. 2012; 7(4)[DOI][PubMed]
  • 13. Kant S, Kumar A, Singh SM. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules. Biochim Biophys Acta. 2012; 1820(11): 1764-73[DOI][PubMed]
  • 14. Agostini M, Almeida L, Bastos D, Ortega R, Moreira F, Seguin F, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. oral abstract. 2012; 114(4): 127
  • 15. Menendez JA, Vellon L, Lupu R. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer. 2006; 16(1): 219-21[DOI][PubMed]
  • 16. Huang HQ, Tang J, Zhou ST, Yi T, Peng HL, Shen GB, et al. Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat. Int J Oncol. 2012; 41(2): 523-32[DOI][PubMed]
  • 17. Xiao D, Shi D, Yang D, Benjamin B, Koch T, Yan B. . Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profoud implications in the action of anticancer prodrugs. Biochemical Pharmacology. Biochem Pharmacol. 2012;
  • 18. Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, et al. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol. 2012; 40(5): 1483-91[DOI][PubMed]
  • 19. Orsolin PC, Silva-Oliveira RG, Nepomuceno JC. Assessment of the mutagenic, recombinagenic and carcinogenic potential of orlistat in somatic cells of Drosophila melanogaster. Food Chem Toxicol. 2012; 50(8): 2598-604[DOI][PubMed]
  • 20. Calderon Guzman D, Hernandez Garcia E, Juarez Jacobo A, Segura Abarca L, Barragan Mejia G, Rodriguez Perez R, et al. Effect of orlistat on lipid peroxidation, Na+, K+ ATPase, glutathione and serotonin in rat brain. Proc West Pharmacol Soc. 2011; 54: 73-7[PubMed]
  • 21. Trichopoulou A, Lagiou P. Worldwide patterns of dietary lipids intake and health implications. Am J Clin Nutr. 1997; 66(4 Suppl): 961S-4S[PubMed]
  • 22. Ahnen DJ, Guerciolini R, Hauptman J, Blotner S, Woods CJ, Wargovich MJ. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects. Clin Gastroenterol Hepatol. 2007; 5(11): 1291-9[DOI][PubMed]
  • 23. Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett. 2008; 18(22): 5838-41[DOI][PubMed]
  • 24. Fernandes Gdos S, Katz A, Calabrich A, Hoff PM. Reversible serum carcinoembryogenic antigen (CEA) elevation due to orlistat use: A case report. Clinics (Sao Paulo). 2010; 65(6): 645-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments